Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 24 03 2021
accepted: 29 06 2021
pubmed: 24 7 2021
medline: 22 12 2021
entrez: 23 7 2021
Statut: ppublish

Résumé

Resection margin status is considered one of the few surgeon-controlled parameters affecting prognosis in pancreatic ductal adenocarcinoma (PDAC). While studies mostly focus on resection margins in pancreatoduodenectomy, little is known about their role in distal pancreatectomy (DP). This study aimed to investigate resection margins in DP for PDAC. Patients who underwent DP for PDAC between October 2004 and February 2020 were included (n = 124). Resection margins and associated parameters were studied in two consecutive time periods during which different pathology examination protocols were used: non-standardized (period 1: 2004-2014) and standardized (period 2: 2015-2020). Microscopic margin involvement (R1) was defined as ≤1 mm clearance. Laparoscopic and open resections were performed in 117 (94.4%) and 7 (5.6%) patients, respectively. The R1 rate for the entire cohort was 73.4%, increasing from 60.4% in period 1 to 83.1% in period 2 (p = 0.005). A significantly higher R1 rate was observed for the posterior margin (35.8 vs. 70.4%, p < 0.001) and anterior pancreatic surface (based on a 0 mm clearance; 18.9 vs. 35.4%, p = 0.045). Pathology examination period, poorly differentiated PDAC, and vascular invasion were associated with R1 in the multivariable model. Extended DP, positive anterior pancreatic surface, lymph node ratio, perineural invasion, and adjuvant chemotherapy, but not R1, were significant prognostic factors for overall survival in the entire cohort. Pathology examination is a key determinant of resection margin status following DP for PDAC. A high R1 rate is to be expected when pathology examination is meticulous and standardized. Involvement of the anterior pancreatic surface affects prognosis.

Sections du résumé

BACKGROUND BACKGROUND
Resection margin status is considered one of the few surgeon-controlled parameters affecting prognosis in pancreatic ductal adenocarcinoma (PDAC). While studies mostly focus on resection margins in pancreatoduodenectomy, little is known about their role in distal pancreatectomy (DP). This study aimed to investigate resection margins in DP for PDAC.
METHODS METHODS
Patients who underwent DP for PDAC between October 2004 and February 2020 were included (n = 124). Resection margins and associated parameters were studied in two consecutive time periods during which different pathology examination protocols were used: non-standardized (period 1: 2004-2014) and standardized (period 2: 2015-2020). Microscopic margin involvement (R1) was defined as ≤1 mm clearance.
RESULTS RESULTS
Laparoscopic and open resections were performed in 117 (94.4%) and 7 (5.6%) patients, respectively. The R1 rate for the entire cohort was 73.4%, increasing from 60.4% in period 1 to 83.1% in period 2 (p = 0.005). A significantly higher R1 rate was observed for the posterior margin (35.8 vs. 70.4%, p < 0.001) and anterior pancreatic surface (based on a 0 mm clearance; 18.9 vs. 35.4%, p = 0.045). Pathology examination period, poorly differentiated PDAC, and vascular invasion were associated with R1 in the multivariable model. Extended DP, positive anterior pancreatic surface, lymph node ratio, perineural invasion, and adjuvant chemotherapy, but not R1, were significant prognostic factors for overall survival in the entire cohort.
CONCLUSIONS CONCLUSIONS
Pathology examination is a key determinant of resection margin status following DP for PDAC. A high R1 rate is to be expected when pathology examination is meticulous and standardized. Involvement of the anterior pancreatic surface affects prognosis.

Identifiants

pubmed: 34296358
doi: 10.1245/s10434-021-10464-6
pii: 10.1245/s10434-021-10464-6
pmc: PMC8677636
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

366-375

Informations de copyright

© 2021. The Author(s).

Références

J Vis Exp. 2020 Feb 1;(156):
pubmed: 32065168
Histopathology. 2008 Jun;52(7):787-96
pubmed: 18081813
Ann Surg Oncol. 2021 Feb;28(2):1079-1087
pubmed: 32583198
Br J Surg. 2015 Nov;102(12):1459-72
pubmed: 26350029
Ann Surg Oncol. 2016 Feb;23(2):585-91
pubmed: 26508153
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
PLoS One. 2016 Sep 16;11(9):e0163266
pubmed: 27636547
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
Br J Surg. 2006 Oct;93(10):1232-7
pubmed: 16804874
Ann Surg. 2015 Nov;262(5):868-73; discussion 873-4
pubmed: 26583678
J Gastrointest Surg. 2006 Dec;10(10):1338-45; discussion 1345-6
pubmed: 17175452
Ann Surg Oncol. 2008 Jun;15(6):1651-60
pubmed: 18351300
Updates Surg. 2020 Jun;72(2):387-397
pubmed: 32266660
Surgery. 2014 Jul;156(1):1-14
pubmed: 24856668
HPB (Oxford). 2016 Jan;18(1):21-8
pubmed: 26776847
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Langenbecks Arch Surg. 2018 Dec;403(8):941-948
pubmed: 30417281
Surg Endosc. 2016 Aug;30(8):3409-18
pubmed: 26514135
J Gastrointest Surg. 2017 Oct;21(10):1620-1625
pubmed: 28766272
Surgery. 2017 Oct;162(4):802-811
pubmed: 28756944
Histopathology. 2009 Sep;55(3):277-83
pubmed: 19723142
World J Surg. 2015 Feb;39(2):493-9
pubmed: 25270344
Ann Surg. 2009 Aug;250(2):177-86
pubmed: 19638919
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
J Hepatobiliary Pancreat Surg. 2004;11(6):402-8
pubmed: 15619016
Surgery. 2015 Jun;157(6):1106-12
pubmed: 25704430
HPB (Oxford). 2009 Feb;11(1):18-24
pubmed: 19590619
HPB (Oxford). 2018 Feb;20(2):175-181
pubmed: 28943397
Surgery. 2012 May;151(5):717-23
pubmed: 22284762
J Clin Oncol. 2009 Jun 10;27(17):2855-62
pubmed: 19398572
Eur J Surg Oncol. 2013 Jun;39(6):559-66
pubmed: 23498362
Ann Surg. 2013 Apr;257(4):731-6
pubmed: 22968073
Ann Surg Oncol. 2017 Nov;24(12):3674-3682
pubmed: 28871564
Surg Endosc. 2018 Jan;32(1):53-61
pubmed: 28643065
Ann Surg. 2019 Dec;270(6):1138-1146
pubmed: 29672406
Ann Surg Oncol. 2021 Aug;28(8):4602-4612
pubmed: 33393031
Ann Surg. 2018 Dec;268(6):1058-1068
pubmed: 28692477
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131

Auteurs

Mushegh A Sahakyan (MA)

The Intervention Centre, Rikshospitalet, Oslo University Hospital, Oslo, Norway. sahakyan.mushegh@gmail.com.
Division of Emergencies and Critical Care, Department of Research and Development, Oslo University Hospital, Oslo, Norway. sahakyan.mushegh@gmail.com.
Department of Surgery N1, Yerevan State Medical University, Yerevan, Armenia. sahakyan.mushegh@gmail.com.

Caroline S Verbeke (CS)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Pathology, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Tore Tholfsen (T)

Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Dejan Ignjatovic (D)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Digestive Surgery, Akershus University Hospital, Lørenskog, Norway.

Dyre Kleive (D)

Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Trond Buanes (T)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Kristoffer Lassen (K)

Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.

Bård I Røsok (BI)

Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Knut Jørgen Labori (KJ)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Bjørn Edwin (B)

The Intervention Centre, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Hepato-Pancreato-Biliary Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH